key: cord-0711018-q90ybmdd
authors: Leiva, Orly; Bhatt, Ankeet S.; Vaduganathan, Muthiah
title: Innovation in Ambulatory Care of Heart Failure in the Era of COVID-19
date: 2020-06-19
journal: Heart Fail Clin
DOI: 10.1016/j.hfc.2020.06.004
sha: 064a1f45ed21ee17c37712e40e8bc4cf4b716d15
doc_id: 711018
cord_uid: q90ybmdd

Despite steady progress over the last 3 decades in advancing drug and device therapies reduce morbidity and mortality in heart failure with reduced ejection fraction, large registries of usual care demonstrate incomplete use of these evidence-based therapies in clinical practice. A large segment of the heart failure population lives in community settings, at times with limited access to care. Most patient-physician interactions occur in ambulatory clinics, including those that span primary care, cardiology, and advanced heart failure. Innovative ambulatory practice models inclusive of multidisciplinary approaches are critically needed. Potential strategies to improve guideline-directed medical therapy include leveraging non-physician clinicians, solidifying transitions of care, incorporating telehealth solutions, and engaging in comprehensive comorbid disease management via multi-disciplinary team structures. These approaches may be particularly relevant in an era of Coronavirus Disease 2019 and associated need for social distancing, further limiting contact with traditional ambulatory clinic settings.

angiotensin II receptor blockers (ARB), angiotensin receptor-neprilysin inhibitors (ARNI), βblockers, mineralocorticoid receptor antagonists (MRA), and most recently, the sodium glucose cotransporter-2 inhibitors (SGLT2i). However, despite these recent advances, less than 1% of patients with HF are simultaneously treated with target doses of multiple evidence-based classes improve delivery of GDMT is utilizing non-physician medical staff under the guidance of HF specialists to engage in more active & frequent therapeutic changes. For instance, clinical pharmacists are experienced members of inpatient and outpatient interdisciplinary care teams and may serve as an important resource to aid in earlier initiation and uptitration. A model of pharmacist involvement in HF consult services in the inpatient setting has led to increased use of GDMT [12] . In the outpatient setting, one small pilot study utilized pharmacists to help manage dose titrations of GDMT. Despite small sample size, this intervention led to target dose β-blocker titration in 78% of patients and a significant reduction in all-cause hospital admissions [13] .

Other studies have also shown reduction in hospital readmissions for HF when pharmacists are used to assist GDMT implementation in the outpatient setting [14] . Similarly, nursing-directed clinics have also been shown to increase adherence and optimize titration of GDMT [15, 16] .

Organizing these non-physician providers in GDMT-specific clinics (Figure 1) represents a strategy to de-link usual care (which may focus on acute care needs and decongestion) and therapeutic optimization [17, 18] . Randomized clinical trials examining an early intensive GDMT uptitration strategy as compared with usual care are underway (NCT03412201). providers when hemodynamics may allow for more aggressive GDMT. For example, one study provided participants a smartphone and a smartwatch along with an application which tracked participant activity data and required them to input daily self-measured blood pressure and bodyweight. While this study was limited in size, a significant increase in quality of life and performance status was reported [32] . In patients with advanced HF, monitoring of pulmonary artery (PA) and intracardiac pressures via implantable devices has already been shown to reduce HF hospitalizations [33, 34] . For example, the CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients trial (CHAMPION) trial showed improved clinical outcomes with longitudinal assessment and access to real-time PA pressure measurements that may be due to improved GDMT in the monitored group [33] . Given interconnectivity and telecommunication advances in the modern-era, telemedicine is poised to become increasingly important in the management of chronic diseases such as HF. 

Patients with heart failure often have comorbid non-cardiac conditions that contributes to morbidity, mortality, and impaired health-related quality of life. In one study, more than 80% of HF patients had at least one non-cardiovascular comorbid condition and 25% had more than three [35] . Patients with HF and comorbid conditions have worse outcomes including increased mortality and HF admissions [35] . Chronic obstructive lung disease (COPD) and anemia have independently been associated with increased HF admissions and poorer outcomes [36] . Patients with comorbid conditions also had more severe HF symptoms including fatigue, dyspnea, pain and anxiety, which may collectively contribute to worse quality of life [37] . Therefore, comprehensive ambulatory management of HF patients should include active surveillance and management of comorbid conditions. In addition, added comorbidity burden increased polypharmacy and may adversely affect adherence. Evaluation and early treatment or prevention of comorbid conditions are crucial to prevent potential exacerbation of HF and provide comprehensive cardiopulmonary and systemic care.

The most commonly identified comorbidities in HF patients are diabetes mellitus, COPD, chronic kidney disease (CKD) and anemia [35, [37] [38] [39] . In patients with diabetes mellitus (both with and without HF), new therapeutic options have emerged, including, the sodium glucose cotransporter-2 inhibitors (SGLT2). SGLT2 inhibitors have been found to decrease HF events in patients with type 2 diabetes mellitus [40] [41] [42] [43] [44] . The landmark Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF) trial additionally demonstrated that dapagliflozin may be helpful in the treatment of patients with established HF with reduced ejection fraction [45] . Cardiologists will need to take a more active role in prescribing these therapies, which have traditionally been considered only for their glucose-lowering potential.

COPD is comorbid with HF and has been associated with increased mortality and hospitalization [46, 47] . In the context of multiple intersecting comorbidities, programs designed to aid patients in medication adherence (and avoidance of potentially harmful or unnecessary therapies) will become increasingly important, particularly as medication burden increases [48] .

Lastly, depression is an often-overlooked comorbidity in HF patients. Depression is comorbid in approximately 22% of patients with HF and has been associated with poor health-related quality of life and is an independent risk factor for subsequent cardiovascular events [49, 50].

Importantly, depression may adversely impact therapeutic and lifestyle adherence [51] . Therefore, early screening and psychiatric support may be an additional avenue to improve adherence in HF patients with concomitant depression.

Vaccination is an important part of global prevention, even more so in patients with chronic diseases such as HF. In particular, vaccination against pulmonary pathogens (influenza and pneumococcus) in HF has some promise in improving outcomes though no large clinical trials have reported yet [52] . There are many plausible mechanisms by which influenza infection may promote worsening HF, including pro-inflammatory acceleration of atherogenesis in addition to direct myocardial depressant effects of inflammatory cytokines. Routine early influenza vaccination has been shown to be effective in patients with atherosclerotic vascular disease and recent acute coronary syndrome [53] . In addition, recent data suggest that early, well-matched consistent influenza vaccination in patients with HF may improve clinical outcomes and reduce rehospitalization rates [54] . Data from a large randomized clinical trial also showed an association between influenza vaccination and improved CV events [55] . Despite this, usual care evidence suggests major gaps in influenza vaccination rates in the US, with increasing refusal rates [56] . In addition, centers performing well with respect to influenza vaccination in HF patients also performed well with respect to other HF quality measures, suggesting that particular centers may have integrated structured approaches to influenza vaccination administration into traditional HF disease management programs. Despite common sense indication for influenza vaccination and clear biological plausibility for benefit in patients with established cardiopulmonary disease, a focal anti-vaccination contingent and strong personal feelings and fears with regards to influenza vaccination may, in part, explain disappointing vaccination rates among patients with cardiovascular disease. New implementation avenues, particular those that may involve direct, patient-facing behavioral economic nudges, are needed to better understand barriers for non-vaccination and strategies for improvement.

As with many chronic cardiometabolic diseases, lifestyle modification is critical as a central tenet of disease management. HF is no exception and thus lifestyle modification interventions should be part of every outpatient HF program and clinic. Structured exercise programs are one such intervention that has been proposed in HF, particularly given the overlap between HF, 

Impact of a Pharmacist-Led Intervention on 30-Day Readmission and Assessment of Factors Predictive of Readmission in African American Men With Heart Failure

Temporal improvement in heart failure survival related to the use of a nurse-directed clinic and recommended pharmacological treatment

Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction

Guideline-Directed Medical Therapy Clinics: A Call to Action for the Heart Failure Team

De novo heart failure: where the 31

Structured telephone support or telemonitoring programmes for patients with chronic heart failure

Designing meaningful outcome parameters using mobile technology: a new mobile application for telemonitoring of patients with heart failure

Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction

Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial

Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry

Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment

analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review

Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study

Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes

Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis

Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions

Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis

Influenza Vaccine in Heart Failure

Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial

Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure

Exercise training in patients with heart failure: clinical outcomes, safety, and indications

Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial

Influence of Baseline Physical Activity Level on Exercise Training Response and Clinical Outcomes in Heart Failure: The HF-ACTION Trial

Impact of multidisciplinary treatment strategy on systolic heart failure outcome

Dietary management of heart failure: room for improvement?

Malnutrition and Cachexia in Heart Failure